Melanie Henry
Primary Care · Hayti, MONPI 1952774275
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,846 of the $3,600 with a category attached, or 79.0%. 19 manufacturers reported payments, led by Coloplast at 24.3% of the total. 2025 is the largest year on record at $1,342, 3.5 times the $387 reported in 2021. Among primary care clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$875
- Johnson & Johnson$857
- AbbVie$599
- Otsuka America Pharmaceutical, Inc.$301
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$195
- Neurocrine Biosciences, Inc.$154
- plus $620 from 13 others
What the payments were for
- Travel & lodging$75421%
- Food & beverage$2,84679%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 49 | $875 |
| Johnson & Johnson | 6 | $857 |
| AbbVie | 52 | $599 |
| Otsuka America Pharmaceutical, Inc. | 15 | $301 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $195 |
| Neurocrine Biosciences, Inc. | 8 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $129 |
| Teva Pharmaceuticals USA, Inc. | 6 | $108 |
| Merck | 6 | $95 |
| Lundbeck LLC | 4 | $71 |
| Teleflex LLC | 2 | $43 |
| Alkermes, Inc. | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| AstraZeneca | 1 | $18 |
| Dendreon Pharmaceuticals LLC | 1 | $17 |
| Axonics, Inc. | 1 | $14 |
| OWP Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$754
How this compares
$3,600 in reported general payments places this provider in the 90th percentile of 106 primary care providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 110 | $394,950 |
| RexultiBrexpiprazole | 180 | $163,304 |
| VraylarCariprazine Hcl | 53 | $73,690 |
| AustedoDeutetrabenazine | 16 | $49,242 |
| Abilify MaintenaAripiprazole | 17 | $47,914 |
| TrintellixVortioxetine Hydrobromide | 98 | $47,127 |
| BelsomraSuvorexant | 29 | $16,127 |
| Paliperidone ErPaliperidone | 45 | $15,065 |
| Olanzapine | 199 | $11,340 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,581 |
| Clozapine | 98 | $8,852 |
| Lurasidone Hcl | 69 | $8,081 |
| Divalproex Sodium | 176 | $7,490 |
| QuviviqDaridorexant Hcl | 14 | $7,427 |
| Aripiprazole | 192 | $6,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $857 | $394,950110 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $301 | $211,218197 claims |
| AbbVieVraylar | $599 | $73,69053 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $108 | $49,24216 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $129 | $47,12798 claims |
| MerckBelsomra | $95 | $16,12729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 106 primary care providers in Missouri.
Other primary care in Hayti
- Danielle ToalCape Girardeau$15K
- Joy MurphySaint Louis$7K
- Katrina SelsorSparta$6K
- Kelly EspositoSaint Louis$6K
- Elizabeth YoungSaint Louis$5K
- Carol HarringtonIndependence$4K
- Heather BealSaint Louis$4K
- Taylor HeathSparta$3K
- Ashley TitchenalSaint Louis$3K
- Avonne RosarioKansas City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.